Search Tag: AnaConDa

ICU Management

2021 28 Sep

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has received market approval for inhaled sedation in Germany. The approval applies to the drug Sedaconda (isoflurane) for administration via the medical device AnaConDa (undergoing name change to Sedaconda ACD) for inhaled sedation in intensive care in Germany....Read more

ICU Management

2021 27 Aug

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the results of the company's pivotal study Sedaconda (SED001) have been published in the highly ranked scientific journal, the Lancet Respiratory Medicine. "We are very pleased that the study is published in Lancet Respiratory Medicine. The results of the study, which is...Read more

ICU Management

2021 20 Jul

Sedana Medical AB (publ) today announced that the company has received a positive outcome for its European registration application for the drug Sedaconda (isoflurane) for inhaled sedation. Sedaconda is indicated for sedation of mechanically ventilated adult patients during intensive care and should only be administered via the medical device AnaConDa....Read more

ICU Management

2020 13 Jan

Sedana Medical AB today announced that the last patient has now been included in the pivotal IsoConDa study. Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020. “This is a true milestone for Sedana Medical . It is extremely gratifying that we keep the schedule in the world's largest study...Read more